methylphenidate modified release tablet - 8 hrs acting / Generic mfg. - LARVOL DELTA

A Rare Phenomenon, Recurrent Acute Dystonia after Withdrawal of 'Methylphenidate-immediate Release Form': A Pediatric Case with ADHD. (PubMed, Clin Psychopharmacol Neurosci) - "Various options such as anticholinergic agents, re-administrating MPH, or turning to monotherapy from combination modalities, can be suggested in treatment, as well as only hydration may also have the benefit of resolving the symptoms, as in the current case. Practitioners should be aware of all possible adverse effects of MPH, even the rebound effect of short-acting forms."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Dystonia • Movement Disorders • Pediatrics • Psychiatry

Effects of methylphenidate and physiotherapeutic treatment on graphomotor movements in children with ADHD. (PubMed, Eur Child Adolesc Psychiatry) - "Graphomotor movement fluency and velocity improves over time across the groups, especially in tasks with eyes closed. We did not find clear evidence for beneficial effects of methylphenidate or physiotherapeutic treatment on children's overall graphomotor movements suggesting that treatments need to be better tailored towards specific and individual deficits in graphomotor movements."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry

[VIRTUAL] A Novel Extended-Release Stimulant Formulation for ADHD (APA 2021) - "The resulting release characteristics allow for customized, sustained release of active drug for up to 24 hours post-dose.The LiquiXR drug delivery technology has already been successfully utilized in the development of treatment options (liquid suspension and chewable tablet) that offer rapid absorption and sustained plasma levels after once- daily dosing: amphetamine extended-release oral suspension (AMPH EROS), methylphenidate for extended-release oral suspension (MEROS), and methylphenidate extended-release chewable tablets (MRCT)...The LiquiXR drug delivery technology provides for an immediate release followed by extended-release profile that demonstrated efficacy in treatment of ADHD for these patient populations, with an acceptable safety profile."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Recent updates in the Alzheimer's disease etiopathology and possible treatment approaches: a narrative review of current clinical trials. (PubMed, Curr Mol Pharmacol) - "The presences of a small number of candidates in the last phase suggest that a large number of candidates have had an undesirable side effect or were unable to pass essential eligibility for future phases. Among successful treatment approaches, clearance of Aβ, recovery of cognitive deficits, and control of acute neuroinflammation are the widely chosen targets. It is predicted that some FDA-approved drugs such as Paracetamol, Risperidone, Escitalopram, Simvastatin, Cilostazoand, and Ritalin-SR could also use in off-label ways for AD. This review improves our ability to recognize novel treatments for AD and suggesting approaches for the clinical trial design for this devastating disease in the near future."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Dementia • Immunology

[VIRTUAL] Why Change? Motivations for Self-Substitution of Illegal Substances Among Treatment Enrolled Individuals (CPDD 2020) - "Substitutions among cocaine users included heroin (14.9%), methylphenidate tablets - RITALIN® (11.8%), illegal methadone (11.3%), and other cocaine administration routes (e.g., smoking crack or injection) (10.7%)... Among treatment-enrolled patients, substitution is the rule rather than the exception. Changes in drug availability appear to have a substantial impact on users’ decisions to substitute. Policy-makers need to be made aware of how supply reduction measures and legal status affect self-substitution, particularly since substitution may constitute a risk factor for multiple drug toxicity."

Clinical

ADHD drug may change brain white matter in boys (Healio) - P=NA, N=98; "MPH also affected the lateral aspect of the truncus of the corpus callosum because of a greater increase in FA among boys treated with the medication, with a standardized effect size of 5.25. This change did not occur among boys receiving placebo or adult men, the researchers wrote."

Clinical data